Russia’s Sputnik V COVID-19 vaccine candidate appears safe and is 91.6% effective

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia – The Lancet

Commentaries: Sputnik V COVID-19 vaccine candidate appears safe and effective – The Lancet AND Russia’s “Sputnik V” COVID Vaccine Makes Strong 91.6 % Efficacy Showing In Peer-Reviewed Trial Results – Health Policy Watch AND Russia’s COVID vaccine 92% effective, even in those over 60 – CIDRAP AND Russia’s Sputnik V vaccine has 92% efficacy in trial – BBC AND Expert reaction to study looking at preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine (Sputnik) trial – Science Media Centre

Commentary on Twitter

NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr

— The Lancet (@TheLancet) February 2, 2021